Abbisko Therapeutics Co.
Latest round
- Series D
Last raised
- Jan 2021
Total raised
- $263M
Investors
- 19
About Abbisko Therapeutics Co.
, Ltd. focuses on producing targeted small molecule drugs for cancer treatment. The company's headquarters is located in Shanghai, China. Dr. Yao-Chang Xu serves as CEO, leading a team with extensive expertise in drug development.Abbisko is primarily engaged in the development and commercialization of innovative therapeutics, focusing on addressing unmet medical needs in oncology. The company's flagship products include a range of small molecule drugs designed to target specific cancer pathways, thereby enhancing treatment efficacy and minimizing side effects. These products are engineered for use in both monotherapy and combination therapy settings, catering to a diverse patient population across various stages of cancer treatment. The therapeutic solutions aim to improve outcomes for patients suffering from advanced solid tumors and hematologic malignancies, with a commitment to advancing personalized medicine.Abbisko generates revenue through a combination of partnerships, direct sales, and collaborations with healthcare providers and research institutions. The company engages in B2B transactions, primarily working with hospitals and specialty clinics that administer its therapeutic products. Revenue streams are augmented through strategic alliances with pharmaceutical companies, which may involve co-development and licensing agreements for its proprietary drug candidates. Additionally, Abbisko's pricing structure is designed to reflect the value provided by its innovative solutions, with contracts often negotiated on a case-by-case basis depending on the treatment regimens and patient accessibility., Ltd. The company aims to launch new oncology products and expand its market presence, particularly focusing on the Asia-Pacific region, where there is a growing demand for innovative cancer therapies. Specific release dates for new products have not been disclosed, but the company's strategy includes significant engagement in markets such as China and Japan.
Who invested in Abbisko Therapeutics Co.
19 investors across 4 rounds
See all investors in Abbisko Therapeutics Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Abbisko Therapeutics Co.
Who invested in Abbisko Therapeutics Co.?
Abbisko Therapeutics Co. has 19 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Abbisko Therapeutics Co. raised?
Abbisko Therapeutics Co. has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Abbisko Therapeutics Co. last raise money?
Abbisko Therapeutics Co.'s most recent round on record is a Series D, in Jan 2021.
What does Abbisko Therapeutics Co. do?
Abbisko Therapeutics Co. is a biotechnology company.
Where is Abbisko Therapeutics Co. headquartered?
Abbisko Therapeutics Co. is headquartered in Shanghai, China.
Which VCs invest in companies like Abbisko Therapeutics Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Abbisko Therapeutics Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Abbisko Therapeutics Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.